350
Participants
Start Date
July 31, 2018
Primary Completion Date
December 15, 2020
Study Completion Date
December 23, 2021
troriluzole
Oral BHV-4157 will be given daily for up to 48 weeks
Placebo oral capsule
Oral matching placebo will be given daily for up to 48 weeks
Columbia University, New York
James J. Peters VAMC, The Bronx
SUNY Upstate Medical University Department of Geriatrics, Syracuse
University of Rochester Medical Center, Rochester
University of Pittsburgh, Pittsburgh
Geisinger Medical Clinic, Wilkes-Barre
Abington Neurological Associates, Willow Grove
Keystone Clinical Studies, LLC, Norristown
Johns Hopkins University, Baltimore
CBRI, Roper Hospital, Charleston
University of Miami, Miami
Brain Matters Research, Delray Beach
USF Health Byrd Alzheimer's Institute, Tampa
Vanderbilt Memory & Alzheimer's Center, Nashville
University of Kentucky, Lexington
Ohio State University, Columbus
Case Western Reserve University, Beachwood
Indiana University, Indianapolis
University of Michigan, Ann Arbor, Ann Arbor
Michigan State University, East Lansing
University of Iowa, Iowa City
Northwestern University, Chicago
Great Lakes Clinical Trials, Chicago
Southern Illinois University, Springfield
Galen Research, Chesterfield
Pennington Biomedical Research Center, Baton Rouge
Tulsa Clinical Research, Tulsa
Xenoscience, Inc., Phoenix
Barrow Neurological Institute, Phoenix
Banner Sun Health Research Institute, Sun City
Cleveland Clinic Lou Ruvo Center, Las Vegas
University of Southern California, Los Angeles
SC3 Research Group - Pasadena, Pasadena
University of California, San Diego, La Jolla
Neurology Center of North Orange County, Fullerton
Oregon Health and Science University, Portland
University of Washington, Seattle
Geriatric and Adult Psychiatry, Hamden
Yale University School of Medicine, New Haven
Ki Health PARTNERS LLC DBA NEW ENGLAND INSTITUTE FOR CLINICAL RESEARCH, Stamford
Northern Light Acadia Hospital, Bangor
Princeton Medical Institute, Princeton
Rhode Island Hospital, Providence
The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases,University of Texas Health Science Center at San Antonio, San Antonio
Lead Sponsor
Alzheimer's Disease Cooperative Study (ADCS)
OTHER
Biohaven Pharmaceuticals, Inc.
INDUSTRY